Nuvation Bio Inc. NUVB

NUVB Company Overview

Nuvation Bio Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for oncology. The company operates within the biotechnology and pharmaceutical industries, with an emphasis on precision cancer treatments designed to address unmet medical needs across solid tumors and other difficult-to-treat cancers. Its primary business model centers on advancing internally developed and acquired drug candidates through clinical development, regulatory approval, and eventual commercialization. Revenue generation has historically been limited because the company remains primarily in the research and development stage, with funding derived mainly from equity financing, strategic transactions, and cash management activities disclosed in public filings.

The company’s pipeline includes targeted oncology programs aimed at molecularly defined patient populations, including therapies directed at ROS1-positive non-small cell lung cancer and other oncogenic drivers. A major strategic differentiator for Nuvation Bio has been its focus on acquiring or licensing promising clinical assets and advancing them through focused development pathways. The company was founded in 2018 by biotechnology entrepreneur David Hung and became publicly traded through a business combination with a special purpose acquisition company in 2021. Since inception, the company has evolved from an early-stage oncology platform into a more diversified clinical oncology developer with multiple investigational programs.